Specialized health services, such as blood and marrow transplantation (BMT), are usually based in large urban centers. Previous research has suggested that rural patients undergoing BMT have a higher risk of death. We performed a cohort study using data from both the Manitoba BMT Program and the provincial Cancer Registry to determine whether patients from the rural areas would have inferior survival after BMT and whether rural patients have reduced access to BMT. A total of 463 adult Manitobans, who underwent BMT between January 1990 and December 2006, were assessed. We analyzed area of residence (rural vs urban), disease and BMT characteristics, and calculated the OS. Patients undergoing autologous and allogeneic transplants were analyzed separately. When adjusted for gender, age at BMT and year of BMT, area of residence was not a significant predictor of mortality. A relative survival analysis was also conducted, and area of residence was again not a significant predictor of mortality. To measure access to BMT in urban vs rural patients, we evaluated all patients with newly diagnosed Hodgkin's Lymphoma (HL) during this same period. Of 432 Manitobans diagnosed with HL, 182 (42%) were rural and 250 (58%) were urban. In contrast, 69% of patients undergoing transplant for HL were urban. In conclusion, using population-based data from a Canadian province, we were unable to show a survival disadvantage for rural patients after controlling for other variables. BMT utilization in rural populations deserves further study.
Introduction
Blood and marrow transplantation (BMT) is a specialized procedure that offers a potential cure for individuals with hematological malignancies, BM failure states and inherited metabolic disorders. Owing to its complexity and expense, BMT is offered in relatively few medical centers. Canada, which has a population of some 30 million people and has an area of nearly 10 million square kilometers, 1 has 19 centers offering autologous BMT and 11 centers 2 that offer allogeneic BMT. The province of Manitoba has one combined autologous and allogeneic BMT center, and it provides services to patients who may live more than 1000 km away.
An American study 3 has shown that living in rural areas is associated with increased mortality in patients receiving autologous BMT, but not allogeneic BMT. The authors postulated that the absence of a relationship among allogeneic BMT patients may be because of a small sample size. An additional study 4 from the same center examined outcomes in patients with lymphoma and found a lower survival rate among patients from rural areas treated by community physicians, but not among rural patients treated by university-based physicians. However, no study has examined the outcome after BMT both in rural and in urban areas of Canada, a country that offers comprehensive medical care to all permanent residents and citizens in a national health insurance system. The first objective of this study is to evaluate the relationship between location of residence and mortality in BMT patients residing in the Canadian province of Manitoba.
One study 5 showed that American patients treated by university-based providers were significantly more likely to have a BMT as part of their treatment regimen as compared with patients treated by community-based providers, but did not find a difference between patients from rural and urban areas overall . We investigated this issue in rural and urban Canadians. Thus, the second objective of this study was to examine BMT utilization among rural vs urban patients diagnosed with Hodgkin's Lymphoma (HL).
Materials and methods
Data were obtained from the Manitoba Blood and Marrow Transplantation Registry (MBMTR), which is a prospective database of consecutive patients who have undergone BMT at CancerCare Manitoba, in Winnipeg, Manitoba, Canada. We examined all adult (age X18 years) patients who resided in Manitoba at the time of their transplant and who underwent BMT between 1 January 1990 and 31 December 2006. Initial data on patients (including age, gender, residence at time of transplantation, disease, stage and previous treatment) were obtained by individual chart review, and, if necessary, by direct contact with the treating physician. Patients are tracked while in hospital, and the registry staff makes regular contact with both the treating physician and the patient after discharge.
Since the inception of the BMT program, all transplants have been performed in a dedicated Leukemia/BMT unit at a tertiary care hospital, with positive pressure air handling and high-efficiency particulate air filtration. In general, eligibility criteria for transplantation included a KPS of X60% (Eastern Cooperative Oncology Group (ECOG) 0-2) and the presence of adequate organ function, as deemed by the treating BMT physician. TBI-based ablative conditioning regimens were used for unrelated donor transplants and lymphoid malignancies, and chemotherapy-based regimens were used for all other patients. In patients receiving allogeneic transplants, stem cell source was either from peripheral blood or from the BM obtained from related or unrelated donors. Since October 2005, reduced-intensity conditioning regimens were used for allogeneic transplant recipients over the age of 55 years. Antimicrobials were used in all patients to prevent viral and bacterial infections, whereas allogeneic BMT recipients received antifungal chemoprophylaxis for at least the duration of the neutropenic period. PCR-based screening for CMV was initiated for allogeneic BMT recipients in 1998. Prophylaxis against pneumocystis pneumonia, consisting of cotrimoxazole or dapsone, was given to autologous and allogeneic BMT recipients for at least 6 and 12 months after BMT, respectively. After BMT, all patients received g-irradiated blood product support, and, as of 1998, all patients received pre-storage leukoreduced products. Other changes that occurred over the study period reflect general trends in BMT indications worldwide, such as a decrement in autologous BMT for breast cancer and in allogeneic BMT for chronic myeloid leukemia.
All cancer diagnoses among individuals in Manitoba are reported to the Manitoba Cancer Registry. The registry includes data such as age, gender, primary residence at time of diagnosis and disease (by ICD code). We obtained data from the Cancer Registry on consecutive adult patients in Manitoba (aged X18 years) diagnosed with HL between 1990 and 2006. HL was chosen for examining BMT utilization for two reasons: first, the relatively uniform diagnosis and coding of HL in the Cancer Registry; and second, BMT has been an accepted treatment modality for relapsed or refractory HL during the study period. 6, 7 Residence was recorded by postal code in both the Cancer Registry and the MBMTR. Patients were stratified into two groups: Urban (Winnipeg and bedroom communities) and rural. Winnipeg is the only urban area in Manitoba (urban areas defined as having a population greater than 50 000 people). 8 For the duration of the study period, there were no medical specialists in hematology and/or oncology who practiced outside the urban area of Winnipeg.
Patients were stratified into urban and rural income quintiles based on the average income associated with their respective postal codes, derived from the Canadian census. Patients were also stratified into high-and low-risk groups, based on their primary disease. 9 Low-risk patients were defined as patients with either acute leukemia or lymphoma in first remission, CML in first chronic phase or a nonmalignant disease. All other patients were defined as high risk.
Analyses were conducted using SPSS (Version 17. 2009., SPSS Inc., Chicago, IL, USA; Kaplan-Meier survival estimates and comparative statistics) and SAS version 9.1 (SAS, SAS Institute, Gary, NC, USA; Cox regression and relative survival analyses) softwares. Patients in both urban and rural groups were compared based on their baseline age, gender, disease risk and income (divided into the two lowest quintiles and the three highest quintiles) using w 2 -tests and Student's t-tests. Separate analyses were conducted for autologous and allogeneic transplant recipients. Owing to the small sample sizes, only the predictors significantly related to the outcome remained in the final model. P-values from type-III test were included in the results.
Two different multivariate survival analyses were used for the first objective. The failure event for both types of analyses was all-cause mortality. The first analysis used a Cox regression model and included the variables of age, gender, disease risk, area of residence, period of BMT and income.
A relative survival analysis was also performed, and included the variables of age, gender, distance from BMT center and period of BMT. Patients were followed up to a maximum of 5 years, as it has been recommended to not exceed this follow-up period in relative survival analysis. 10 Relative survival analysis compares ratios of the observed survival from the cohort with the expected survival of a comparable group from the general population, matched to the patients with the variables of interest, to determine predictors of excessive mortality. 11 Therefore, the variable of disease risk, which is patient-specific and not found in the general population, could not be included. In addition, if life expectancy is lower in rural areas, 12 relative survival would determine whether the mortality ratio between urban and rural patients differ from the mortality ratio between urban and rural residents from the general population. Relative survival is considered to be more appropriate than Cox proportional hazards regression for calculating survival in population-based data registries. 13 Finally, for the second objective, the number of HL cases was determined from cancer registry data in both rural and urban patients, and these were compared with the number of BMT procedures for HL in rural and urban patients using a w Table 1 . There were no significant differences in gender, age, year of transplant, disease risk or income between rural and urban patients. The median follow-up time for surviving patients was 3.11 years.
To examine the first objective, autologous and allogeneic BMT patients were first analyzed separately and stratified by area of residence and plotted using Kaplan-Meier survival curves (Figures 1 and 2 ). The 5-year OS in patients undergoing autologous transplantation was 59.0% in patients from urban areas and only 46.0% in patients from rural areas. In allogeneic transplantation, 5-year OS was 43.0% in patients from urban areas and 36.2% in patients from rural areas.
Cox multivariable regression models were performed separately for autologous and allogeneic BMT patients. The variables included in the full model comprised disease risk, income, period of transplant and distance from the transplant center. Two variables (period of transplant and age at BMT) violated the proportional hazard assumption, and a time interaction variable was required for each of those variables in the analysis. Income and location of residence could not be included in the same model because the income variable provides quintiles for urban and rural residents separately (that is, colinearity). However, income was not related to mortality in a univariate analysis. The results of the univariate and multivariate analyses are shown in Table 2 . Area of residence was non-significantly related to mortality in patients undergoing autologous transplantation in the univariate analysis (hazard ratio (HR) 1.44, 95% CI 1.00-2.06), although this achieved near significance. In the multivariate analysis, the HR for area of residence decreased (HR 1.30, 95% CI 0.90-1.88). The period in which the patient underwent BMT was the only variable significantly associated with mortality. Those who underwent BMT between 1990 and 1996 had a higher mortality than those who underwent BMT between 2002 and 2006 (HR 2.82, 95% CI 1.62-4.89). Area of residence was not related to mortality in patients undergoing allogeneic transplantation in the univariate analysis (HR 1.08, 95% CI 0.75-1.55). When controlling for other variables in the multivariate analysis, neither area of residence (HR 1.04, 95% CI 0.72-1.51) nor period were related to mortality (Table 3) .
Relative survival models were also used. The covariates included in this analysis were age, gender, location of residence and period of BMT. As in the Cox regression model, when adjusting for covariates, income and location of residence could not be included in the same model. In the univariate analysis, area of residence for patients undergoing autologous BMT was non-significantly related to excess mortality (excess HR (EHR) 1.50, 95% CI 1.00-2.25), although, as in the Cox multivariate analysis, this achieved near significance. The effect of area of residence decreased in the multivariate analysis (EHR 1.31, 95% CI 0.87-1.99). Non-significant relationships were found between area of residence and excess mortality for patients undergoing allogeneic transplantation without (EHR 1.01, 95% CI 0.69-1.48) and with covariates (EHR 1.00, 95% CI 0.68-1.47).
Each analysis was repeated with patients stratified into three groups: urban patients, patients living in rural areas less than 200 km from the transplant center and patients living more than 200 km from the transplant center. These results did not differ from patients stratified on rural or urban residence.
Finally, we examined access to BMT in urban and rural patients. A total of 432 Manitobans were diagnosed with HL between 1990 and 2006 and 48 autologous transplants were performed for this indication. Of the 432 patients with HL, 250 (58%) were urban and 182 (42%) were rural. In contrast, 33(69%) patients undergoing BMT for HL were urban and 15(31%) were rural. The w 2 -test showed a nonsignificant difference in the proportion of urban and rural Manitoban HL patients who underwent BMT (P ¼ 0.146).
Discussion
Our results partially confirm those of a previous study by Rao et al. 3 Their study showed a significant increase in mortality in rural patients undergoing autologous transplantation, but not in patients undergoing allogeneic transplantation. They postulated that this might be due Urban vs rural outcomes in BMT K Paulson et al to different follow-up patterns of patients undergoing autologous and allogeneic transplantation. In addition, they commented that the analyses for allogeneic transplant patients might have lacked statistical power owing to a small sample size. In our study, we found non-significant relationships between area of residence and mortality in the multivariate Cox regression analyses and relative survival analyses of patients undergoing both autologous and allogeneic transplantation. Despite these non-significant relationships, a pattern emerged in the results: the mortality ratios between rural and urban autologous transplant patients were consistently higher than those found in the allogeneic setting. The HR for autologous patients was 1.30 in the Cox multivariate analysis and the EHR was 1.31 in the relative survival analysis, whereas the hazard and EHRs for allogeneic transplant patients ranged from 1.00 to 1.08. This may provide additional evidence that rural patients undergoing autologous transplantation are at a greater risk of mortality, and that rural patients undergoing allogeneic transplantation are not at a greater risk of mortality than urban patients. In general, patients receiving an autologous BMT are discharged from hospital relatively soon after engraftment and are permitted to return to their home communities much sooner than the more medically Urban vs rural outcomes in BMT K Paulson et al complex allogeneic BMT recipients. Even after patients are discharged home, transplant physicians are likely to follow allogeneic BMT recipients more frequently, often in tertiary care centers, to manage complications such as GVHD and post-BMT infections. These different patterns in follow-up may explain why rural autologous transplant patients might have an inferior outcome. One difference between the two studies is that the current study included analyses that compared mortality rates of patients with their expected rate of mortality (that is, relative survival). This is an advantageous analysis because a significant difference between location of residence found in Cox regression analyses may be in part because of differences in life expectancy between the urban vs rural residents in the general population.
There are several reasons why non-significant results would be expected in Canada. Rural Americans are less likely to be insured than urban Americans, and lack of health insurance is associated with increased mortality, 14 which might partially explain the increased mortality seen in the study by Rao et al. In addition to universal health care, in some cases, travel costs for Canadians from rural areas are covered, reducing issues of access. BMT is an insured service in Canada, and patients who are deemed eligible for transplant have all hospitalization costs, physician visits and medications in hospital covered by provincial health insurance programs. The same situation exists in many European countries that have universal health insurance coverage. This may not be necessarily true for Americans who lack private health insurance and are not covered by government-funded programs such as Medicare. Given that rural Americans are less likely to be insured than urban Americans, 14 this may be a reason why our results were somewhat different than Rao's study.
In Manitoba, the existence of a single oncology/BMT program based in one city has led to the creation of satellite rural oncology centers that are closely linked to programs such as Manitoba's Community Cancer Network. This program supports oncology-oriented training and resources for health care professionals in rural centers and links them to cancer centers in academic university hospitals. In addition, there is a telecommunication system that provides video linkage from more than 50 community cancer network sites to the university-based transplant center, Abbreviation: 95% CL ¼ 95% confidence limit.
Urban vs rural outcomes in BMT K Paulson et al allowing specialist physicians, nurses and pharmacists to conduct follow-up appointments at a distance. It is possible that programs such as these lead to improved outcomes among patients from rural areas. Low income is associated with increased mortality in patients undergoing allogeneic BMT. 15 However, income was not a predictor of mortality in the current study. It is possible that Canada's universal health care system is protective against some of the disadvantages related to lower socioeconomic status (for example, universal health care may ensure easier and more regular access to health care). This would be advantageous in assuring timely access to diagnosis, treatment and follow-up. At least one study has shown that income is a less significant predictor of mortality in Canada as compared with the United States. 16 However, the non-significant relationship between income and mortality of the current study may be due a combination of two factors that produced inadequate statistical power: the income variable provides separate quintiles for urban and rural residents, which would give a minimum of four categories (urban/rural status and low/high income), and relatively small sample sizes.
This study has several limitations. First, the analyses may have lacked statistical power. Post hoc analyses of the data used for the Cox multivariable analyses indicated that between 600 and 700 autologous patients would be needed to achieve statistical significance. Another limitation is that, we were unable to collect information that was not initially recorded in the transplant or cancer registries, such as details on how patients were followed up in the community. Third, our results comparing patients from Winnipeg (a population of some 650 000) with rural patients may not be generalizable to jurisdictions with megacities.
For HL patients, there was a non-significant difference in the probability of receiving a BMT when comparing urban and rural residence at diagnosis. However, the number of patients from rural areas who received a BMT (n ¼ 15) likely provided inadequate statistical power. However, it is also possible that primary care providers in rural areas are not fully aware of the need for timely referral for BMT. Alternatively, caregivers or patients may be choosing treatment options other than BMT because of the expectation of prolonged in-patient care in a distant urban hospital. This is a question that deserves further study.
In conclusion, we did not show a significant difference in mortality between rural and urban patients who underwent either autologous or allogeneic transplantation. These findings have important implications for health care providers and public health officials. As the delivery of health care to rural and remote individuals is largely a function of the health care system, it is not surprising that differences exist between studies addressing this question in Table 3 Relative survival predicting 5-year overall mortality Abbreviation: CL ¼ 95% confidence limit.
Urban vs rural outcomes in BMT K Paulson et al different jurisdictions. Health care providers caring for patients in rural or remote locations should be aware of barriers to accessing care, and health care administrators should look for innovative new ways to deliver care to these individuals. We recommend that further studies examine whether distance from a transplant center is an independent risk factor for mortality after BMT and establish the factors that are responsible for explaining rural-urban disparities.
